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Human Intrahepatic Regulatory TCells Are
Functional, Require IL-2 FromEffector
Cells for Survival, andAre Susceptible to Fas
Ligand-Mediated Apoptosis
Yung-Yi Chen,1,2* Hannah C. Jeffery,1,2* Stuart Hunter,1 Ricky Bhogal,1 Jane Birtwistle,3 Manjit Kaur Braitch,1 Sheree Roberts,1
Mikaela Ming,1 Jack Hannah,1 Clare Thomas,1 Gupse Adali,1 Stefan G. H€ubscher,4 Wing-Kin Syn,5,6 Simon Afford,1,2
Patricia F. Lalor,1,2 David H. Adams,1,2 and Ye H. Oo1,2
Regulatory T cells (Treg) suppress T effector cell proliferation and maintain immune homeostasis. Autoimmune liver dis-
eases persist despite high frequencies of Treg in the liver, suggesting that the local hepatic microenvironment might affect
Treg stability, survival, and function. We hypothesized that interactions between Treg and endothelial cells during recruit-
ment and then with epithelial cells within the liver affect Treg stability, survival, and function. To model this, we explored
the function of Treg after migration through human hepatic sinusoidal-endothelium (postendothelial migrated Treg [PEM
Treg]) and the effect of subsequent interactions with cholangiocytes and local proinﬂammatory cytokines on survival and
stability of Treg. Our ﬁndings suggest that the intrahepatic microenvironment is highly enriched with proinﬂammatory
cytokines but deﬁcient in the Treg survival cytokine interleukin (IL)-2. Migration through endothelium into a model mim-
icking the inﬂamed liver microenvironment did not affect Treg stability; however, functional capacity was reduced. Further-
more, the addition of exogenous IL-2 enhanced PEM Treg phosphorylated STAT5 signaling compared with PEMCD8.
CD4 and CD8 T cells are the main source of IL-2 in the inﬂamed liver. Liver-inﬁltrating Treg reside close to bile ducts
and coculture with cholangiocytes or their supernatants induced preferential apoptosis of Treg compared with CD8 effector
cells. Treg from diseased livers expressed high levels of CD95, and their apoptosis was inhibited by IL-2 or blockade of
CD95. Conclusion: Recruitment through endothelium does not impair Treg stability, but a proinﬂammatory microenviron-
ment deﬁcient in IL-2 leads to impaired function and increased susceptibility of Treg to epithelial cell-induced Fas-medi-
ated apoptosis. These results provide a mechanism to explain Treg dysfunction in inﬂamed tissues and suggest that IL-2
supplementation, particularly if used in conjunction with Treg therapy, could restore immune homeostasis in inﬂammatory
and autoimmune liver disease. (HEPATOLOGY 2016; 00:000–000)
CD4
1CD251 CD127low FOXP31 regulatory
T cells (Treg) maintain peripheral self-
tolerance by suppressing T effector cell pro-
liferation and function.(1,2) Treg depletion or dys-
function leads to autoimmunity in mice and IPEX
syndrome in humans. Treg dysfunction or an imbal-
ance between Treg and effector cells in tissue will
determine the outcome of inﬂammation.(3,4)
Abbreviations: ANOVA, analysis of variance; BEC, biliary epithelial cell; ELISA, enzyme-linked immunosorbent assay; FASL, Fas ligand; IL,
interleukin; HSEC, hepatic sinusoidal endothelial cell; IFN-c, interferon-c; LITreg, liver-inﬁltrating regulatory T cell; PEM Treg, postendothelial
migrated Treg; SEM, standard error of the mean; Th 1, T helper 1; Th 17, T helper 17; TNF-a, tumor necrosis factor a; Treg, regulatory T cell.
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A
HE STUDY OF LIVER D I S E ASEST
MERICAN ASSOCIATION FOR
Intrahepatic Treg increase in parallel with effector T
cells during chronic hepatitis(5) demonstrates that the
presence of Treg in the liver does not prevent ongoing
hepatic inﬂammation. Whether this is due to dys-
functional Treg or overwhelming effector responses is
not known.
Understanding the fate of Treg in the inﬂamed liver is
crucial, because Treg recruited to the liver from blood via
hepatic sinusoids(6) enter the hepatic microenvironment
enriched with proinﬂammatory cytokines. The process
of recruitment and/or exposure to this inﬂammatory
microenvironment could affect Treg stability, survival,
and function. Recruitment through endothelium can
affect the differentiation and activation of various leuko-
cyte subsets, and Treg can switch toward a T helper 1
(Th 1) or T helper 17 (Th 17) lineage in an inﬂamma-
tory environment.(7,8) Furthermore, intrahepatic lym-
phocytes are removed by activation-induced cell death
triggered by receptors such as CD95 (APO-1/Fas),
leading to resolution of inﬂammation. Thus, differential
susceptibility to apoptosis could affect the balance of
Treg and T effector cells at inﬂammatory sites.
(9,10) Treg
are highly sensitive to CD95-mediated apoptosis,(11)
and interleukin (IL)-2-dependent phosphorylation of
STAT5 is crucial for their proliferation, differentiation,
and survival.(12) We reported previously that many
intrahepatic Treg lack evidence of STAT5 phosphoryla-
tion, suggesting that the inﬂammatory liver microenvir-
onment is hostile to Treg survival and function.
(13)
In the present study, we report that recruitment
through endothelium into a model of the inﬂamed
liver microenvironment reduces the suppressive
capacity of Treg and a lack of local IL-2 enhances their
susceptibility to Fas-mediated apoptosis induced by
epithelial cells. These ﬁndings support the therapeutic
potential of IL-2 therapy to restore local Treg function
in inﬂammatory liver diseases.
Materials and Methods
TISSUES AND BLOOD
Venous blood was obtained from healthy volunteers or
patients with hemochromatosis who were admitted to the
Liver Unit at the Queen Elizabeth Hospital, Birming-
ham, UK(5) (Local Research Ethics Committee reference
no. 04/Q2708/41) and liver tissues from patients under-
going liver transplantation for inﬂammatory liver diseases,
including primary biliary cirrhosis, primary sclerosing
cholangitis, alcoholic liver disease, and autoimmune hep-
atitis. Normal liver was obtained from donor liver tissue
surplus to clinical requirements (Local Research Ethics
Committee reference no. 06/Q2708/11, 98/CA5192).
ISOLATIONOFLIVER
INFILTRATINGLYMPHOCYTES,
BILIARYEPITHELIALCELLS, AND
PRIMARYHUMANHEPATIC
SINUSOIDALENDOTHELIALCELLS
Liver-inﬁltrating lymphocytes,(5) biliary epithelial
cells (BECs),(14) and hepatic sinusoidal endothelial
cells (HSECs)(15) were prepared and isolated from
fresh liver tissue as described previously.(13)
POSTENDOTHELIAL
TRANSMIGRATED Treg AND CD8
1
T CELL FUNCTIONAL ASSAYS
HSECs were plated and grown on six-well collagen I
precoated Transwell inserts (3 lm; Greiner Bio-One)
until conﬂuent. Cells were then stimulated with 10 ng/mL
interferon-c (IFN-c) and 10 ng/mL tumor necrosis factor
a (TNF-a) (both Peprotech) for 24 hours to mimic the
inﬂamed environment. After washing, the lower chamber
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was ﬁlled with either Roswell Park Memorial Institute
1640 (RPMI-1640) medium (Gibco) supplemented with
0.05% bovine serum albumin or inﬂamed liver condi-
tioned supernatant prepared by incubating 1 g of tissue in
4 mL serum-free RPMI 1640 for 24 hours. The superna-
tant was then centrifuged and ﬁltered (0.22 lm-pore).
Freshly isolated Treg or CD8
1 T cells were then added to
the upper chamber of the Transwell insert in 0.05% bovine
serum albumin/RPMI-1640 and allowed tomigrate across
the endothelial cell monolayer into the lower chamber for
24 hours. The postendothelial transmigrated Treg (PEM
Treg) or postendothelial transmigrated CD8
1 T (PEM
CD8) cells were collected for experiments (Treg suppres-
sion assay, biliary coculture assay, phosphorylated STAT5
assay, and Treg plasticity assay).
PEM Treg AND CD8 APOPTOSIS
ASSAY
BECs were seeded into 24-well collagen I precoated
plates, grown until conﬂuent, and stimulated with 10 ng/
mL IFN-c and 10 ng/mL TNF-a (Peprotech) for 24
hours. PEM Treg or PEM CD8 cells were cocultured
with these BECs or with BEC supernatant for 24 hours,
and apoptosis was analyzed by way of ﬂow cytometric
staining using Annexin and 7AAD (BD Pharmingen).
STATISTICAL ANALYSIS
Differences between treatments were evaluated by way of
Student t test or one-way analysis of variance (ANOVA),
followed by Bonferroni multiple comparison test using
GraphPad Prism version 6.0 (GraphPad Software). P <
0.05 was considered statistically signiﬁcant. Data are pre-
sented as themean6 standard error of themean (SEM).
See the Supporting Information for details regarding
immunohistochemistry, confocal microscopy, enzyme-
linked immunosorbent assay (ELISA), ﬂow cytometry,
isolation of peripheral blood Treg and CD8 and assays
of Treg function, plasticity, and response to IL-2.
Results
FRESHLY ISOLATED HUMAN
LIVER INFILTRATING Treg ARE
ACTIVATED, NONEXHAUSTED,
MEMORY CELLS
We compared the frequency and surface phenotype of
liver-inﬁltrating CD41CD25highCD127low Treg (LITreg)
in different inﬂammatory liver diseases with normal liver
tissue (Fig. 1A,B) and with liver-inﬁltrating CD8 cells
(Supporting Fig. S1C). Treg isolated from normal and
diseased livers differed in their expression of Treg-associ-
ated functional surface receptors CD26, CD39, and
CD69 (Fig. 1B). Very low expression of PD1 was
observed on LITreg in both normal and diseased patients
(965% versus 9.562%) (Fig. 1B) but high levels of
CD44 were observed on LITreg (7966% versus 8765%)
and liver-inﬁltrating CD8 cells (7569% versus 9064%)
(Supporting Fig. S1C). LITreg exhibited a memory phe-
notype: CD45ROhighCD45RAlow and CCR7low
(8567%) and inﬂamed liver tissue contained small popu-
lations of central memory CD45RAnegCCR7pos
(4.763%) and tissue resident memory CD45RA-
posCCR7neg (763%) LITreg (Fig. 1C,D).
PROINFLAMMATORY CYTOKINES
ARE ELEVATED IN THE
INFLAMED LIVER
ENVIRONMENT, BUT THIS DOES
NOT ALTER INTRAHEPATIC Treg
STABILITY
We explored the intrahepatic microenvironment by
measuring proinﬂammatory cytokines in supernatants
from inﬂamed human liver tissue. Diseased liver super-
natants contained higher concentrations of IL-6 (8960
6 4257 pg/mL), IL-8 (24,033 6 16,589 pg/mL), IL-
12 (61 6 30 pg/mL), IFN-c (32 6 7 pg/mL), and IL-
1b (363 6 88 pg/mL) compared with normal liver
supernatants (Fig. 2A).
We then examined the stability of intrahepatic Treg in
the hepatic microenvironment by modeling recruitment
and intrahepatic conditions in vitro. Blood Treg that had
transmigrated across TNF-a and IFN-c-stimulated
HSECs had a phenotype similar to the LITreg pheno-
type, allowing us to use them to model the inﬂamed liver
in vitro (Fig. 2B). PEM Treg were migrated across
stimulated HSECs into either control media or superna-
tants from inﬂamed liver tissue cultures (Supporting Fig.
S5) and secretion of IL-10, IL-17, and IFN-c by Treg
measured 24 hours postmigration (Fig. 2C) and expres-
sion of FOXP3, ROR, and Tbet analyzed up to 3 days
(Fig. 2D, Supporting Fig. S2). A subset of LITreg
expressed CD161 (20%) or IL-6 receptor (27%). We
did not detect AhR expression (Fig. 2E).
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PEM Treg REMAIN
FUNCTIONALLY SUPPRESSIVE
After migration across endothelium into inﬂamed
tissue supernatants, Treg maintained their ability to
suppress the proliferation of T effector cells (Fig. 3A,
Supporting Fig. S5A). Freshly isolated Treg were func-
tionally suppressive (Treg/T effector cell ratio 5 1:8)
before any cell contact (Fig. 3Ai) and after contact
with endothelium (Treg/T effector cell ratio 5 1:4) but
before transmigration (Fig. 3Aii). After transmigration
across TNF-a and IFN-c-stimulated HSECs into
control media (Fig. 3Aiii), Treg had a reduced suppres-
sive capacity at a 1:2 ratio. This was reduced further
after migration into inﬂamed liver supernatant with
suppression only seen at a 1:1 cell ratio (Fig. 3Aiv).
LITreg expressed cell surface receptors associated
with suppressive function (Fig. 3B,C) including
CTLA-4 and CD147,(16) whereas factors associated
with cytolytic activity, granzyme-B, and perforin were
expressed at higher levels on LICD8 T cells com-
pared with LITreg (53% versus 8% and 27% versus
8%). There were no signiﬁcant differences in the
expression of LAG-3 (21% versus 8%), CD137 (13%
versus 4%), and TIM-3 (8% versus 4%) between
LITreg and LICD8 (Fig. 3B,C).
                                                                                                                                      
FIG. 1. Frequency and phenotype of intrahepatic Treg in inﬂamed human livers. Freshly isolated LITreg from human explanted livers
were phenotyped by ﬂow cytometry. LITreg were gated as CD4
1CD25highCD127low. (A) Frequency of LITreg in normal livers and dif-
ferent diseased livers. (B) Surface marker expressions of LITreg from normal livers, alcoholic liver disease livers, and autoimmune disease
livers (see Supporting Fig. S1C for surface marker expressions of LICD8 cells from different diseased livers). LITreg (deﬁned as
CD31CD41CD127lowCD25high) were screened for expression of surface markers, CD26, CD39, CD44, CD69, and PD1. Data are
presented as the mean 6 SEM (n 5 6; one-way ANOVA followed by Bonferroni multiple comparison test). **P < 0.05. (C, D) Matu-
ration status of LITreg. Frequencies of CD45RA
2 memory (CD45RA2CCR72), CD45RO1 memory (CD45RO1CCR72), central
memory (CD45RA2CCR71), and na€ıve (CD45RA1 CCR71) LITreg populations were determined by way of ﬂow cytometry. Repre-
sentative dot plots (C) and summary data (D) of LITreg maturation status are shown. Data are presented as the mean 6 SEM (n 5 6).
                                                                                                                                      
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LIVER RESIDENT Treg AND CD8
RESIDE AROUND Fas LIGAND
(FASL)-POSITIVE BILE DUCTS
FOXP31 LITreg were detected throughout the hepatic
parenchyma, ﬁbrous septa, and sinusoids as well as close
to bile ducts in portal tracts (Fig. 4A-C) in inﬂamed liver
tissue. CD95 ligand (FASL/CD178) was detected on
CK191 bile ducts in all inﬂammatory liver disease but
not on normal liver tissue (Fig. 4D),(14) with no difference
in expression between different liver diseases.
CD95 EXPRESSION IS INCREASED
ON LIVER INFILTRATING Treg
AND MEDIATES CELL
APOPTOSIS IN RESPONSE TO
BEC FASL
Treg from diseased livers were more susceptible to
apoptosis (Fig. 5A). LITreg expressed CD154, OX40,
CD40, CD95, and CD27 and high levels of CD95 in
all diseased livers (Fig. 5B). Liver-inﬁltrating CD8 cells
were expressed at lower levels (Fig. 5C) Freshly isolated
                                                                                                                                      
FIG. 2. Intrahepatic microenvironment is enriched with proinﬂammatory cytokines and PEM Treg are not plastic to other T cell lineages. (A)
Cytokine proﬁles of supernatants collected from normal and diseased livers. Tissue from normal or diseased liver was cultured for 24 hours in
RPMI-1640 medium at 1 g/mL, and the concentrations of cytokines IL-6, IL-8, IL-12, IL-15, IFN-c, TNF-a, and IL-1b were measured
using a Bio-Plex Pro bead-based multiplex kit. Data are presented as the mean 6 SEM (n 5 6; one-way ANOVA with Bonferroni multiple
comparison test). *P< 0.05. (B-D) Treg phenotype before and after migration across stimulated hepatic sinusoidal endothelium. Treg freshly iso-
lated from peripheral blood were transmigrated through monolayers of IFN-c- and TNF-a-stimulated hepatic sinusoidal endothelial cells into
either RPMI-1640 medium (control) or liver supernatant and phenotyped by way of ﬂow cytometry. Expression of markers including CD26,
CD39, CD44, PD1, CD147, CTLA-4, CD95, CD27, and CXCR3 before and after transendothelial migration into RPMI-1640 medium are
shown (B). Data are presented as the mean 6 SEM (n 5 6; one-way ANOVA followed by Bonferroni multiple comparison test). *P < 0.05.
Expressions of cytokines including IL-10, IL-17, and IFN-c at 24 hours (C) and transcription factors FOXP3, ROR, and Tbet at 3 days (D)
were measured before and after migration into RPMI-1640 medium or liver supernatant (see Supporting Fig. S2 for expression of transcription
factors up to 3 days of culture in inﬂamed liver supernatants). Data are presented as the mean 6 SEM (n 5 4; one-way ANOVA). *P  0.05.
(E) Expression of CD161, IL-6 receptor, and intracellular AhR by LITreg directly ex vivo was shown. Data are presented as the mean 6 SEM
(n5 6; one-way ANOVA followed by Bonferroni multiple comparison test). *P< 0.05; **P< 0.01; ***P< 0.005
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Treg and CD8 cells were transmigrated across TNF-a
and IFN-c-stimulated hepatic sinusoidal endothelium
into either control media, stimulated BEC superna-
tant, or contact with BECs (Fig. 6, Supporting Fig.
S5B). Treg underwent apoptosis in this model, whereas
very few CD8 T cells did. Treg apoptosis in response to
contact with BECs or exposure to BEC supernatant
was prevented by blocking CD95 ligand or by the
addition of IL-2 (Fig. 6). Apoptotic immune cells
were present around the bile duct, and we observed
FOXP3 Treg and caspase-3 dual-positive apoptotic
cells in peribiliary regions in tissue slides (Fig. 6C).
We detected high expression of CD27 on LITreg and
CD70 the ligand for CD27 on liver-inﬁltrating dendritic
                                                                                                                                      
FIG. 3. Intrahepatic Treg remain functional and express Treg functional markers. (A) Treg representative of intrahepatic Treg pheno-
type were generated by transmigration of freshly isolated blood Treg across TNF-a- and IFN-c-stimulated human sinusoidal endothe-
lium into RPMI-1640 control medium or inﬂamed liver supernatant for 24 hours. The suppressive function of Treg was analyzed by
testing their ability to suppress the proliferation of CellTrace Violet prestained CD4 T effector cells using Miltenyi Treg suppression
inspector. Treg populations compared included: (i) Treg directly isolated, without contact with any cells or supernatant; (ii) Treg in con-
tact with endothelium but not transmigrated; (iii) PEM Treg migrated into control RPMI media; and (iv) PEM Treg migrated into
liver supernatant. (B) Comparison of the expressions of Treg functional markers by freshly isolated human LITreg and CD8 T cells.
Data are presented as the mean 6 SEM (n 5 5; one-way ANOVA followed by Bonferroni multiple comparison test). *P < 0.05; **P
< 0.01; ***P < 0.005. (C) Representative ﬂow cytometry overlays for each functional marker on LITreg (CD3
1CD41CD25highC-
D127low) (top panel) and LICD8 (CD31CD81) (bottom panel).
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FIG. 4. Human diseased liver bile ducts expressing FASL and LITreg are present across liver lobules, with some residing in the peri-
biliary region. Immunohistochemistry (A-D) and confocal ﬂuorescence staining (Biii) of parafﬁn-embedded human liver sections for
FOXP3, CD8, CK19 (biliary epithelial cell marker), and FASL are shown. (A) intrahepatic FOXP31 Treg are present across the
parenchyma (i), septa (ii), and portal tract (iii). (B) LICD81 T cells reside close to bile ducts in the portal tracts in diseased human
liver sections (Bi) alcoholic liver disease (ALD), (Bii) primary biliary cirrhosis (PBC), (Biii) Localization of CD8 cells on bile ducts in
AIH liver tissue (red 5 CD8 [phycoerythrin]; green 5 bile ducts/CK19 [ﬂuorescein isothiocyanate]; blue 5 nuclear stain [40,6-diami-
dino-2-phenylindole]). (C) Localization of FOXP31 cells around the bile duct in diseased livers (Ci) autoimmune hepatitis (AIH),
(Cii) hepatitis C virus (HCV), (Ciii) non A non B seronegative hepatitis. (D) Expression of FASL (right panel) by human CK19-
expressing bile ducts (left panel) in normal and diseased livers.
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cells. However, recombinant CD70 had no effect on Treg
or CD8 T cell proliferation (Supporting Fig. S4).
EFFECTOR T CELLS ARE THE
MAIN SOURCE OF
INTRAHEPATIC IL-2 AND Treg
RESPOND BY
PHOSPHORYLATION OF STAT5
IL-2 was nearly undetectable in supernatants pre-
pared from normal and chronic liver disease tissues
(Fig. 7A). Secretion of IL-2 by human hepatocytes,
HSECs, stromal cells, and biliary epithelial cells was
minimal (Fig. 7B). IL-2 expression by liver-inﬁltrating
activated CD4/CD8 cells was observed by way of ﬂow
cytometry (Fig. 7C) and secreted IL-2 was detected in
the supernatant of liver-inﬁltrating CD4 and CD8
lymphocytes after stimulation with anti-CD3/CD28
beads, suggesting that effector lymphocytes are the
main source of IL-2 in inﬂamed livers (Fig. 7D).
A high level of STAT5 phosphorylation was
induced in 80%-90% of Treg, both non-transmigrated
and PEM Treg (Fig. 8, Supporting Fig. S4), and was
not affected by transmigration into the inﬂamed liver
microenvironment (Fig. 8). Signiﬁcantly fewer CD8
cells (27%-36%) responded compared with Treg (Sup-
porting Fig. S4), and the level of phosphorylated
STAT5 generated was also signiﬁcantly greater in Treg
than in CD8 T cells (Fig. 8). Thus, IL-2-CD25 sig-
naling and STAT5 phosphorylation remained intact in
Treg after transmigration into the inﬂamed hepatic
microenvironment.
Discussion
Functionally active Treg are required to suppress
effector cells and maintain immune homeostasis,(13)
and the balance of Treg and T effector cells will con-
tribute to the outcome of liver inﬂammation.(17) Ther-
apeutic modulation of tissue resident Treg has potential
for treating autoimmune liver diseases.(17,18) Treg enter
the liver from blood via hepatic sinusoids(5) before
being localized within the liver in response to signals
from the hepatic stromal compartment, hepatocytes,
and cholangiocytes.(19) Once Treg have migrated across
the hepatic sinusoid, they are exposed to cytokines
including IL-1b, IL-6, IL-8, IL-12, and IFN-c in the
inﬂamed hepatic microenvironment (Fig. 2). This
proinﬂammatory milieu has the potential to inﬂuence
the stability and function of intrahepatic Treg.
(20) We
observed that PEM Treg that had migrated through
activated endothelium into liver tissue supernatants
showed no changes in FOXP3, RORc, or Tbet expres-
sion at 3 days, suggesting that Treg differentiation is
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FIG. 5. Apoptotic potential and expression of the TNF receptor CD95 is increased on LITreg in diseased livers. (A) The apoptotic
potential of LITreg in both normal and diseased livers was assessed by way of ﬂow cytometry with Annexin 5 staining directly ex vivo.
(B, C) Expression of TNF superfamily (TNFSF) and TNF receptor superfamily (TNFRSF) markers by LITreg
(CD31CD41CD127lowCD25high) (B) and liver-inﬁltrating CD8 (CD31CD81) (C) in normal livers (white bar 5 normal liver) and
diseased livers (black bar 5 diseased liver). Data are presented as the mean 6 SEM (n 5 6; one-way ANOVA followed by Bonfer-
roni multiple comparison test). *P < 0.05.
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not affected by the liver milieu. In particular, the lack
of ligand-activated transcription factor aryl hydrocar-
bon receptor and low levels of CD161, which are asso-
ciated with Th 17 polarity, suggest few cells
differentiate into Th 17 cells within the inﬂamed envi-
ronment.(21-23)
The frequency of LITreg is increased across all liver
diseases,(24) and these cells are not exhausted, with very
low expression of PD-1 and high levels of CD69 and
maintained functional properties(25,26) (Fig. 3Aiv). LITreg
exposed to a liver microenvironment maintain high levels
of CD39, an ectonucleotidase used by Treg to generate
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FIG. 6. Apoptosis of PEM Treg but not CD8 is FASL dependent and can be rescued by blocking FASL or by supplementing with
IL-2. Treg and CD81 T cells were transmigrated across TNF-a- and IFN-c-stimulated human sinusoidal endothelium to obtain posten-
dothelial migrated cells, which were then cocultured with BECs or BEC supernatant in the presence or absence of recombinant IL-2 or
anti-FASL antibody. Apoptosis was analyzed using ﬂow cytometry for Annexin V. (A) Representative dot plots of apoptosis for Treg and
CD8 before and after endothelial migration. (B, C) Apoptosis of PEM Treg (B) and PEM CD8 cells (C) with either BECs or BEC
supernatant in the presence or absence of IL-2 or anti-FASL (one-way ANOVA followed by Bonferroni multiple comparison tests). **P
 0.05. (D) Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling revealed that apoptotic immune
cells were present around bile ducts. (E) Dual staining of FOXP3 (brown) and caspase-3 (blue) in different diseased livers.
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immunosuppressive adenosine from extracellular nucleo-
tides.(27) Low expression of CD39 has been reported in
autoimmune liver disease, and our data suggest that the
hepatic microenvironment cannot explain this ﬁnding.(28)
Similarly, LITreg expressed high levels of CD44, which
has been associated with FOXP3 expression and sup-
pressive function.(29) After transendothelial migration
into inﬂamed liver supernatant, Treg maintained IL-10
                                                                                                                                      
FIG. 7. IL-2 is deﬁcient in the liver microenvironment, and activated T lymphocytes are the source of IL-2. (A) IL-2 concentrations in
normal and inﬂamed liver tissue supernatants are shown. Chronic diseased and normal liver tissues were diced and cultured for 24 hours in
RPMI-1640 medium at 1 g/mL, and the concentration of IL-2 was measured by way of ELISA. (B) Minimal IL-2 synthesis by liver-
resident cells under normal and inﬂamed conditions. Cultures of primary BECs, HSECs, hepatocytes, stellate cells, and ﬁbroblasts from
human livers were treated with the inﬂammatory cytokines TNF-a (10 ng/mL) and IFN-c (100 ng/mL) or left untreated, and the concen-
tration of IL-2 in 24-hour supernatants was determined by way of Luminex. Data are presented as the mean 6 SEM (n 5 3). (C, D)
Intrahepatic CD41 and CD81 T cells express and secrete IL-2 upon T cell receptor activation. CD41 and CD81 T cells were isolated
from normal and diseased human liver tissues by way of cell sorting and were cultured for 12 hours at 100 cells/mL with or without anti-
CD3/anti-CD28 stimulation 4 cells/bead. (C) IL-2 expression was examined by way of ﬂow cytometry. (Ci) Representative ﬂow cytometry
dot plots for IL-2 production by stimulated (CD3/CD28 beads) or unstimulated CD4 and CD8 T cells in the presence or absence of addi-
tional PMA and ionomycin stimulation. (Cii, Ciii) Summary frequencies for IL-2 expression without (Cii) and with (Ciii) additional PMA
and ionomycin stimulation. (D) IL-2 secretion was examined by way of ELISA. PMA, phorbol 12-myristate 13-acetate.
                                                                                                                                      
CHEN, JEFFERY, ET AL. HEPATOLOGY, Month 2016
10
secretion and CD147 expression, a marker of activated
and suppressive Treg.
(16) In addition, we also observed an
enrichment of CTLA-4 expression in LITreg. CTLA-4
interacts with and removes CD80/CD86 from dendritic
cells by way of transendocytosis, resulting in impaired
costimulation via CD28 and is thus critical for Treg func-
tion.(30) Overall, LITreg are equipped with key surface
markers and intracellular cytokines required to execute
their suppressive capacity.(31,32) These ﬁndings are
encouraging for proposed studies of adoptive Treg therapy
in autoimmune and inﬂammatory liver diseases because
they suggest that therapeutic cells will remain functional
and will not differentiate into effector cells in an inﬂam-
matory environment.(17)
We detected LITreg and LICD8 cells throughout
the parenchyma and ﬁbrous septa as well as around
bile ducts in patients with liver disease. Biliary epithe-
lial cells can secrete chemokines that localize
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FIG. 8. STAT5 phosphorylation is func-
tionally intact in response to supplemented
IL-2 in postendothelial migrated Treg in
the liver microenvironment. STAT5 phos-
phorylation in pre-endothelial migrated and
PEM Treg and CD8 cells in response to
IL-2 stimulation is shown. Peripheral blood
mononuclear cells were transmigrated over-
night across 24-hour TNF-a- and IFN-c-
stimulated human sinusoidal endothelium
into RPMI-1640 medium or inﬂamed liver
supernatant. Postendothelial migrated cells
and non-transmigrated cells were collected
into separate fractions and were stimulated
for 10 minutes with 0 or 100 IU/mL IL-2.
(A, B) Phosphorylated STAT5 (pY694)
expression by (A) CD41CD251CD1272
Treg and (B) CD8 cells in the fractions was
examined by way of ﬂow cytometry in the
absence of IL-2 stimulation (untreated) and
after 10 minutes of treatment with 100 IU/
mL IL-2. (C) Comparison of the percen-
tages of Treg and CD8 cells expressing
phosphorylated STAT5 after treatment
with IL-2. (D) Comparison of the median
ﬂuorescence intensity (MFI) of STAT5
phosphorylation in Treg and CD8 cells after
treatment with IL-2. Data are presented as
the mean 6 SEM (n 5 4; paired t test).
*P < 0.05, **P < 0.01, ***P < 0.0001. Sta-
tistical tests compare cells from the same
fraction (either untreated and IL-2 treated
Treg or CD8 cells (A and B) or IL-2
treated Treg and CD8 cells (C and D)).
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lymphocytes to portal tracts.(5,13,33,34) We recently
reported that VCAM-1 on bile ducts supports effector
T cells survival by binding to a4b1,(35) but apoptosis
pathways affecting different lymphocyte subsets in the
inﬂamed liver are poorly understood. BECs express
FASL, which can induce T cell death by activating
Fas. Thus, expression or secretion of FASL by BECs
could contribute to intrahepatic T cell apoptosis.(36)
Circulating Treg are highly susceptible to CD95-
FASL-dependent apoptosis but not to TCR-mediated
cell death in contrast to effector T cells.(11) Treg in the
tumor undergo CD95-dependent cell death as a conse-
quence of FASL expression by tumor cells.(37) We have
reported previously that BECs express FASL in inﬂam-
matory liver diseases,(14) but we have not explored the
role of Fas in the differential fate of bile duct-associated
Treg and CD8 cells. In the present study, we demonstrate
that PEM Treg are more susceptible to CD95-FASL-
mediated apoptosis either in contact with BECs or in
response to BEC supernatant compared with PEM
CD8 cells. Treg could be rescued by blocking FASL on
BECs or in the inﬂamed biliary supernatant. If apoptosis
of Treg affects only those in contact with bile ducts, and
not those elsewhere in the liver, this may not have a sub-
stantial effect on the overall frequency of Treg in the dis-
eased liver. In addition, the total frequency of Treg in the
inﬂamed liver will depend on other factors, including the
balance between recruitment, retention, proliferation,
and exit of cells from the liver.
IL-2 is a crucial cytokine for Treg survival that activates
STAT5 phosphorylation in response to activation of the
IL-2 receptor. IL-2 can selectively expand Treg popula-
tions in vitro and in vivo.(38,39) We detected minimal IL-
2 in both the normal and inﬂamed liver microenviron-
ment, which might account in part for reduced Treg func-
tional capacity in the inﬂammatory tissue. The
intrahepatic source of IL-2 is activated in CD4 and CD8
cells, which may be rapidly consumed by both effector
and Treg for their survival and proliferation.
(40,41) Exoge-
nous IL-2 restored levels of STAT5 phosphorylation
and protected Treg from Fas-mediated apoptosis but had
no effect on CD8 T cells. Thus, the lack of IL-2 in the
inﬂamed liver microenvironment may result in unop-
posed Fas-mediated Treg apoptosis as well as contributing
to defective intrahepatic LITreg function. Because the
requirement for IL-2 is much higher for CD8 cells, they
may depend on different survival mechanisms. This is in
agreement with a previous study on the effect of IL-2 on
peripheral blood lymphocyte subsets.(42) This enhanced
phosphorylation of STAT5 in Treg compared with CD8
cells in response to IL-2 occurred in the presence and
absence of cytokine-enriched inﬂamed hepatic superna-
tant, suggesting that the differential effect of IL-2 on
Treg compared with effector cells is maintained in an
inﬂammatory environment. This ﬁnding provides sup-
port for the therapeutic manipulation of LITreg by treat-
ing these patients with IL-2 along with Treg therapy in
the future to maintain functional and surviving LITreg.
In conclusion, we show for the ﬁrst time that LITreg
are phenotypically stable within the inﬂamed hepatic
environment and exhibit minimal plasticity. They
remain functionally suppressive but are susceptible to
apoptosis via the Fas pathway mediated by FASL on
bile ducts, and this can be inhibited by exogenous IL-
2. Therefore, IL-2 therapy may successfully restore
intrahepatic Treg numbers and function in liver disease.
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